Definium Therapeutics financials
$38.31−0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$75.1M | -$59.2M |
| Net income | -$159.0M | -$77.1M |
| Net margin | — | — |
| Diluted EPS | $-1.44 | $-0.71 |
| EBITDA | -$75.1M | -$59.2M |
| Operating cash flow | -$52.8M | -$42.6M |
| Free cash flow | -$52.8M | -$42.6M |
| Diluted shares | 110.7M | 108.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $655.3M | $262.5M |
| Short-term investments | $428.6M | $110.9M |
| Total debt | $36.5M | $40.8M |
| Total assets | $1.11B | $401.3M |
| Total liabilities | $194.2M | $122.4M |
| Shareholders' equity | $918.7M | $278.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology